Cayman
Showing 17251–17400 of 45550 results
-
D-Serine is the dextrorotary isomer of the non-essential amino acid L-serine and a co-agonist of NMDA receptors.{54313} It is formed by conversion of L-serine by serine racemase and found primarily in the brain.{28640,54314} D-Serine binds to the glycine site of the NMDA receptor and potentiates glutamate-induced currents in oocytes expressing various subunit combinations (EC50s = 0.17-0.32 µM) more potently than glycine.{54313,54314} It reverses deficits in prepulse inhibition with prepulses of 69 and 73 decibels (dB), but not 81 dB, and increases the time spent in the target quadrant of the Morris water maze in mice with a mutant form of serine racemase (SrrY269*) when administered at a dose of 600 mg/kg.{54315} Serum levels of D-serine are decreased in patients with schizophrenia.{54316}
Brand:CaymanSKU:31197 - 50 gAvailable on backorder
D-threo Sphinganine (d18:0) is a synthetic bioactive sphingolipid and stereoisomer of sphinganine (d18:0) (Item No. 10007945) and L-erythro sphinganine (d18:0) (Item No. 24374).{40752} It induces autophagy in HCT116 cells when used at a concentration of 12 μM. D-threo Sphinganine (d18:0) is metabolized via sphinganine N-acyltransferase and sphinganine kinase in vivo in rat liver.{40753} [Matreya, LLC. Catalog No. 1851]
Brand:CaymanSKU:24375 - 1 mgAvailable on backorder
D-threo-Biopterin is a pterin originally isolated from D. discoideum.{52419} It enhances luminol (Item No. 16803) chemiluminescence induced by the oxidant chloramine-T in a cell-free assay when used at a concentration of 100 μM.{52420}
Brand:CaymanSKU:29986 - 10 mgAvailable on backorder
D-threo-Biopterin is a pterin originally isolated from D. discoideum.{52419} It enhances luminol (Item No. 16803) chemiluminescence induced by the oxidant chloramine-T in a cell-free assay when used at a concentration of 100 μM.{52420}
Brand:CaymanSKU:29986 - 25 mgAvailable on backorder
D-threo-Biopterin is a pterin originally isolated from D. discoideum.{52419} It enhances luminol (Item No. 16803) chemiluminescence induced by the oxidant chloramine-T in a cell-free assay when used at a concentration of 100 μM.{52420}
Brand:CaymanSKU:29986 - 5 mgAvailable on backorder
D-threo-PPMP is a glucosylceramide (GlyCer) synthetase inhibitor.{28272},{37030} It is the active enanantiomer and enzymatic inhibitory component of the racemic DL-threo-PPMP (Item No. 17236). In MDCK kidney epithelial cells, D-threo-PPMP induces a 70% reduction in cell growth in vitro at 20 µM and significantly inhibits DNA synthesis at 3 µM.{11391} [Matreya, LLC. Catalog No. 1865]
Brand:CaymanSKU:22677 -Out of stock
D-Xylulose is a ketopentose, a monosaccharide containing five carbon atoms and a ketone functional group.{30892} It is converted from xylitol in the glucoronate-xylulose pathway. D-Xylulokinase catalyzes the ATP-dependent phosphorylation of D-xylulose to produce xylulose 5-phosphate, which is linked to the pentose-phosphate pathway.{32650}
Brand:CaymanSKU:20830 -Out of stock
D-Xylulose is a ketopentose, a monosaccharide containing five carbon atoms and a ketone functional group.{30892} It is converted from xylitol in the glucoronate-xylulose pathway. D-Xylulokinase catalyzes the ATP-dependent phosphorylation of D-xylulose to produce xylulose 5-phosphate, which is linked to the pentose-phosphate pathway.{32650}
Brand:CaymanSKU:20830 -Out of stock
D-Xylulose is a ketopentose, a monosaccharide containing five carbon atoms and a ketone functional group.{30892} It is converted from xylitol in the glucoronate-xylulose pathway. D-Xylulokinase catalyzes the ATP-dependent phosphorylation of D-xylulose to produce xylulose 5-phosphate, which is linked to the pentose-phosphate pathway.{32650}
Brand:CaymanSKU:20830 -Out of stock
D-Xylulose is a ketopentose, a monosaccharide containing five carbon atoms and a ketone functional group.{30892} It is converted from xylitol in the glucoronate-xylulose pathway. D-Xylulokinase catalyzes the ATP-dependent phosphorylation of D-xylulose to produce xylulose 5-phosphate, which is linked to the pentose-phosphate pathway.{32650}
Brand:CaymanSKU:20830 -Out of stock
D-α-Hydroxyglutaric acid (D-2-HG) is an α-hydroxy acid that is over-produced in the human neurometabolic disease D-2-hydroxyglutaric aciduria (D-2-HGA).{26892} It is normally synthesized from 2-ketoglutarate (2-KG) by hydroxyacid-oxoacid transhydrogenase (HOT), although defects in HOT are not known to be associated with D-2-HGA.{26892} Instead, type I D-2-HGA involves mutations in D-2-hydroxyglutarate dehydrogenase, which converts D-2-HG back to 2-KG.{26892} Type II D-2-HGA results from gain-of-function mutations in isocitrate dehydrogenase 2 (IDH2), causing it to supplement HOT in converting 2-KG to D-2-HG.{26891,26772} In bacteria, this α-hydroxy acid may be synthesized from oxalate and propionyl-coenzyme A by an α-hydroxyglutaric acid synthetase.{26893}
Brand:CaymanSKU:25895 - 1 mgAvailable on backorder
D-α-Hydroxyglutaric acid (D-2-HG) is an α-hydroxy acid that is over-produced in the human neurometabolic disease D-2-hydroxyglutaric aciduria (D-2-HGA).{26892} It is normally synthesized from 2-ketoglutarate (2-KG) by hydroxyacid-oxoacid transhydrogenase (HOT), although defects in HOT are not known to be associated with D-2-HGA.{26892} Instead, type I D-2-HGA involves mutations in D-2-hydroxyglutarate dehydrogenase, which converts D-2-HG back to 2-KG.{26892} Type II D-2-HGA results from gain-of-function mutations in isocitrate dehydrogenase 2 (IDH2), causing it to supplement HOT in converting 2-KG to D-2-HG.{26891,26772} In bacteria, this α-hydroxy acid may be synthesized from oxalate and propionyl-coenzyme A by an α-hydroxyglutaric acid synthetase.{26893}
Brand:CaymanSKU:25895 - 10 mgAvailable on backorder
D-α-Hydroxyglutaric acid (D-2-HG) is an α-hydroxy acid that is over-produced in the human neurometabolic disease D-2-hydroxyglutaric aciduria (D-2-HGA).{26892} It is normally synthesized from 2-ketoglutarate (2-KG) by hydroxyacid-oxoacid transhydrogenase (HOT), although defects in HOT are not known to be associated with D-2-HGA.{26892} Instead, type I D-2-HGA involves mutations in D-2-hydroxyglutarate dehydrogenase, which converts D-2-HG back to 2-KG.{26892} Type II D-2-HGA results from gain-of-function mutations in isocitrate dehydrogenase 2 (IDH2), causing it to supplement HOT in converting 2-KG to D-2-HG.{26891,26772} In bacteria, this α-hydroxy acid may be synthesized from oxalate and propionyl-coenzyme A by an α-hydroxyglutaric acid synthetase.{26893}
Brand:CaymanSKU:25895 - 25 mgAvailable on backorder
D-α-Hydroxyglutaric acid (D-2-HG) is an α-hydroxy acid that is over-produced in the human neurometabolic disease D-2-hydroxyglutaric aciduria (D-2-HGA).{26892} It is normally synthesized from 2-ketoglutarate (2-KG) by hydroxyacid-oxoacid transhydrogenase (HOT), although defects in HOT are not known to be associated with D-2-HGA.{26892} Instead, type I D-2-HGA involves mutations in D-2-hydroxyglutarate dehydrogenase, which converts D-2-HG back to 2-KG.{26892} Type II D-2-HGA results from gain-of-function mutations in isocitrate dehydrogenase 2 (IDH2), causing it to supplement HOT in converting 2-KG to D-2-HG.{26891,26772} In bacteria, this α-hydroxy acid may be synthesized from oxalate and propionyl-coenzyme A by an α-hydroxyglutaric acid synthetase.{26893}
Brand:CaymanSKU:25895 - 5 mgAvailable on backorder
D-α-Hydroxyglutaric Acid (D-2-HG) is an α-hydroxy acid that is over-produced in the human neurometabolic disease D-2-hydroxyglutaric aciduria (D-2-HGA).{26892} It is normally synthesized from 2-ketoglutarate (2-KG) by hydroxyacid-oxoacid transhydrogenase (HOT), although defects in HOT are not known to be associated with D-2-HGA.{26892} Instead, type I D-2-HGA involves mutations in D-2-hydroxyglutarate dehydrogenase, which converts D-2-HG back to 2-KG.{26892} Type II D-2-HGA results from gain-of-function mutations in isocitrate dehydrogenase 2, causing it to supplement HOT in converting 2-KG to D-2-HG.{26891,26772} In bacteria, this α-hydroxy acid may be synthesized from oxalate and propionyl-coenzyme A by an α-hydroxyglutaric acid synthetase.{26893}
Brand:CaymanSKU:11605 - 10 mgAvailable on backorder
D-α-Hydroxyglutaric Acid (D-2-HG) is an α-hydroxy acid that is over-produced in the human neurometabolic disease D-2-hydroxyglutaric aciduria (D-2-HGA).{26892} It is normally synthesized from 2-ketoglutarate (2-KG) by hydroxyacid-oxoacid transhydrogenase (HOT), although defects in HOT are not known to be associated with D-2-HGA.{26892} Instead, type I D-2-HGA involves mutations in D-2-hydroxyglutarate dehydrogenase, which converts D-2-HG back to 2-KG.{26892} Type II D-2-HGA results from gain-of-function mutations in isocitrate dehydrogenase 2, causing it to supplement HOT in converting 2-KG to D-2-HG.{26891,26772} In bacteria, this α-hydroxy acid may be synthesized from oxalate and propionyl-coenzyme A by an α-hydroxyglutaric acid synthetase.{26893}
Brand:CaymanSKU:11605 - 100 mgAvailable on backorder
D-α-Hydroxyglutaric Acid (D-2-HG) is an α-hydroxy acid that is over-produced in the human neurometabolic disease D-2-hydroxyglutaric aciduria (D-2-HGA).{26892} It is normally synthesized from 2-ketoglutarate (2-KG) by hydroxyacid-oxoacid transhydrogenase (HOT), although defects in HOT are not known to be associated with D-2-HGA.{26892} Instead, type I D-2-HGA involves mutations in D-2-hydroxyglutarate dehydrogenase, which converts D-2-HG back to 2-KG.{26892} Type II D-2-HGA results from gain-of-function mutations in isocitrate dehydrogenase 2, causing it to supplement HOT in converting 2-KG to D-2-HG.{26891,26772} In bacteria, this α-hydroxy acid may be synthesized from oxalate and propionyl-coenzyme A by an α-hydroxyglutaric acid synthetase.{26893}
Brand:CaymanSKU:11605 - 25 mgAvailable on backorder
D-α-Hydroxyglutaric Acid (D-2-HG) is an α-hydroxy acid that is over-produced in the human neurometabolic disease D-2-hydroxyglutaric aciduria (D-2-HGA).{26892} It is normally synthesized from 2-ketoglutarate (2-KG) by hydroxyacid-oxoacid transhydrogenase (HOT), although defects in HOT are not known to be associated with D-2-HGA.{26892} Instead, type I D-2-HGA involves mutations in D-2-hydroxyglutarate dehydrogenase, which converts D-2-HG back to 2-KG.{26892} Type II D-2-HGA results from gain-of-function mutations in isocitrate dehydrogenase 2, causing it to supplement HOT in converting 2-KG to D-2-HG.{26891,26772} In bacteria, this α-hydroxy acid may be synthesized from oxalate and propionyl-coenzyme A by an α-hydroxyglutaric acid synthetase.{26893}
Brand:CaymanSKU:11605 - 250 mgAvailable on backorder
D,L-1′-Acetoxychavicol acetate is a natural compound first isolated from the rhizomes of ginger-like plants. It has a wide array of cellular effects that may be largely explained by its ability to inhibit exportin 1 and prevent the export of proteins from the nucleus.{31360,31361} In this way, D,L-1′-acetoxychavicol acetate reduces several intracellular signaling pathways, including NF-κB, impacting inflammation, cancer, viral replication, and other processes.{31359,31361,31362}
Brand:CaymanSKU:19649 -Available on backorder
D,L-1′-Acetoxychavicol acetate is a natural compound first isolated from the rhizomes of ginger-like plants. It has a wide array of cellular effects that may be largely explained by its ability to inhibit exportin 1 and prevent the export of proteins from the nucleus.{31360,31361} In this way, D,L-1′-acetoxychavicol acetate reduces several intracellular signaling pathways, including NF-κB, impacting inflammation, cancer, viral replication, and other processes.{31359,31361,31362}
Brand:CaymanSKU:19649 -Available on backorder
D,L-1′-Acetoxychavicol acetate is a natural compound first isolated from the rhizomes of ginger-like plants. It has a wide array of cellular effects that may be largely explained by its ability to inhibit exportin 1 and prevent the export of proteins from the nucleus.{31360,31361} In this way, D,L-1′-acetoxychavicol acetate reduces several intracellular signaling pathways, including NF-κB, impacting inflammation, cancer, viral replication, and other processes.{31359,31361,31362}
Brand:CaymanSKU:19649 -Available on backorder
D,L-1′-Acetoxychavicol acetate is a natural compound first isolated from the rhizomes of ginger-like plants. It has a wide array of cellular effects that may be largely explained by its ability to inhibit exportin 1 and prevent the export of proteins from the nucleus.{31360,31361} In this way, D,L-1′-acetoxychavicol acetate reduces several intracellular signaling pathways, including NF-κB, impacting inflammation, cancer, viral replication, and other processes.{31359,31361,31362}
Brand:CaymanSKU:19649 -Available on backorder
D,L-Buthionine-(S,R)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase that induces 100% inhibition at a concentration of 10 μM in an enzyme assay.{36246} It is selective for γ-glutamylcysteine synthetase, lacking activity at glutamine synthetase at concentrations up to 500 μM. D,L-Buthionine-(S,R)-sulfoximine (32 mmol/kg, i.p.) reduces renal glutathione in mice without inducing abnormal behavior or convulsions. It has antiparasitic activity, eliminating T. brucei from the bloodstream of infected mice via depletion of intratrypanosomal glutathione and induction of oxidative stress at a dose of 4 mmol/kg.{36247} D,L-Buthionine-(S,R)-sulfoximine is an isomeric mixture of L-buthionine-S-sulfoxime, L-buthionine-R-sulfoxime, D-buthionine-S-sulfoxime, and D-buthionine-R-sulfoxime.
Brand:CaymanSKU:23691 - 1 gAvailable on backorder
D,L-Buthionine-(S,R)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase that induces 100% inhibition at a concentration of 10 μM in an enzyme assay.{36246} It is selective for γ-glutamylcysteine synthetase, lacking activity at glutamine synthetase at concentrations up to 500 μM. D,L-Buthionine-(S,R)-sulfoximine (32 mmol/kg, i.p.) reduces renal glutathione in mice without inducing abnormal behavior or convulsions. It has antiparasitic activity, eliminating T. brucei from the bloodstream of infected mice via depletion of intratrypanosomal glutathione and induction of oxidative stress at a dose of 4 mmol/kg.{36247} D,L-Buthionine-(S,R)-sulfoximine is an isomeric mixture of L-buthionine-S-sulfoxime, L-buthionine-R-sulfoxime, D-buthionine-S-sulfoxime, and D-buthionine-R-sulfoxime.
Brand:CaymanSKU:23691 - 250 mgAvailable on backorder
D,L-Buthionine-(S,R)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase that induces 100% inhibition at a concentration of 10 μM in an enzyme assay.{36246} It is selective for γ-glutamylcysteine synthetase, lacking activity at glutamine synthetase at concentrations up to 500 μM. D,L-Buthionine-(S,R)-sulfoximine (32 mmol/kg, i.p.) reduces renal glutathione in mice without inducing abnormal behavior or convulsions. It has antiparasitic activity, eliminating T. brucei from the bloodstream of infected mice via depletion of intratrypanosomal glutathione and induction of oxidative stress at a dose of 4 mmol/kg.{36247} D,L-Buthionine-(S,R)-sulfoximine is an isomeric mixture of L-buthionine-S-sulfoxime, L-buthionine-R-sulfoxime, D-buthionine-S-sulfoxime, and D-buthionine-R-sulfoxime.
Brand:CaymanSKU:23691 - 5 gAvailable on backorder
D,L-Buthionine-(S,R)-sulfoximine is an inhibitor of γ-glutamylcysteine synthetase that induces 100% inhibition at a concentration of 10 μM in an enzyme assay.{36246} It is selective for γ-glutamylcysteine synthetase, lacking activity at glutamine synthetase at concentrations up to 500 μM. D,L-Buthionine-(S,R)-sulfoximine (32 mmol/kg, i.p.) reduces renal glutathione in mice without inducing abnormal behavior or convulsions. It has antiparasitic activity, eliminating T. brucei from the bloodstream of infected mice via depletion of intratrypanosomal glutathione and induction of oxidative stress at a dose of 4 mmol/kg.{36247} D,L-Buthionine-(S,R)-sulfoximine is an isomeric mixture of L-buthionine-S-sulfoxime, L-buthionine-R-sulfoxime, D-buthionine-S-sulfoxime, and D-buthionine-R-sulfoxime.
Brand:CaymanSKU:23691 - 500 mgAvailable on backorder
D13 is an acylhydrazone antifungal.{53336} It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection.
Brand:CaymanSKU:29818 - 1 mgAvailable on backorder
D13 is an acylhydrazone antifungal.{53336} It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection.
Brand:CaymanSKU:29818 - 10 mgAvailable on backorder
D13 is an acylhydrazone antifungal.{53336} It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection.
Brand:CaymanSKU:29818 - 25 mgAvailable on backorder
D13 is an acylhydrazone antifungal.{53336} It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection.
Brand:CaymanSKU:29818 - 5 mgAvailable on backorder
D2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.{20293,20296} D2PM is also used in organic synthesis to prepare the Corey-Bakshi-Shibata catalyst.{20423} This product is intended for forensic purposes.
Brand:CaymanSKU:11160 - 10 mgAvailable on backorder
D2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.{20293,20296} D2PM is also used in organic synthesis to prepare the Corey-Bakshi-Shibata catalyst.{20423} This product is intended for forensic purposes.
Brand:CaymanSKU:11160 - 5 mgAvailable on backorder
D2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.{20293,20296} D2PM is also used in organic synthesis to prepare the Corey-Bakshi-Shibata catalyst.{20423} This product is intended for forensic purposes.
Brand:CaymanSKU:11160 - 50 mgAvailable on backorder
D609 is a xanthate and a competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC; Ki = 6.4 µM).{26211} It has no effect on bacterial phosphatidylinositol-specific PLC, bovine pancreatic PLA2, or phospholipase D.{26213} D609 reduces sphingomyelin synthase activity by 55.5 and 90.5% in membrane preparations when used at concentrations of 100 and 200 mg/ml, respectively.{26214} Similar to other xanthates, D609 has antioxidant, antiviral, and anti-tumor activities.{26213} In addition, it has anti-inflammatory actions, inhibiting LPS-stimulated expression of nitric oxide synthase (NOS) in phagocytes (IC50 = 20 µg/ml) and IL-1β-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells.{26212,3364}
Brand:CaymanSKU:- D609 is a xanthate and a competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC; Ki = 6.4 µM).{26211} It has no effect on bacterial phosphatidylinositol-specific PLC, bovine pancreatic PLA2, or phospholipase D.{26213} D609 reduces sphingomyelin synthase activity by 55.5 and 90.5% in membrane preparations when used at concentrations of 100 and 200 mg/ml, respectively.{26214} Similar to other xanthates, D609 has antioxidant, antiviral, and anti-tumor activities.{26213} In addition, it has anti-inflammatory actions, inhibiting LPS-stimulated expression of nitric oxide synthase (NOS) in phagocytes (IC50 = 20 µg/ml) and IL-1β-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells.{26212,3364}
Brand:CaymanSKU:- D609 is a xanthate and a competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC; Ki = 6.4 µM).{26211} It has no effect on bacterial phosphatidylinositol-specific PLC, bovine pancreatic PLA2, or phospholipase D.{26213} D609 reduces sphingomyelin synthase activity by 55.5 and 90.5% in membrane preparations when used at concentrations of 100 and 200 mg/ml, respectively.{26214} Similar to other xanthates, D609 has antioxidant, antiviral, and anti-tumor activities.{26213} In addition, it has anti-inflammatory actions, inhibiting LPS-stimulated expression of nitric oxide synthase (NOS) in phagocytes (IC50 = 20 µg/ml) and IL-1β-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells.{26212,3364}
Brand:CaymanSKU:- D609 is a xanthate and a competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC; Ki = 6.4 µM).{26211} It has no effect on bacterial phosphatidylinositol-specific PLC, bovine pancreatic PLA2, or phospholipase D.{26213} D609 reduces sphingomyelin synthase activity by 55.5 and 90.5% in membrane preparations when used at concentrations of 100 and 200 mg/ml, respectively.{26214} Similar to other xanthates, D609 has antioxidant, antiviral, and anti-tumor activities.{26213} In addition, it has anti-inflammatory actions, inhibiting LPS-stimulated expression of nitric oxide synthase (NOS) in phagocytes (IC50 = 20 µg/ml) and IL-1β-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells.{26212,3364}
Brand:CaymanSKU:-
Cdc25 dual-specific protein tyrosine phosphatases are important for cell cycle progression and often overexpressed in cancers. Through the removal of inhibitory phosphates, they function to catalyze the activation of cyclin-Cdk complexes. DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.{17980,28275,28276} At 20 µM, it has been shown to arrest asynchronous PC-3 prostate cancer cells in G2/M phase.{28276}
Brand:CaymanSKU:-Available on backorder
Cdc25 dual-specific protein tyrosine phosphatases are important for cell cycle progression and often overexpressed in cancers. Through the removal of inhibitory phosphates, they function to catalyze the activation of cyclin-Cdk complexes. DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.{17980,28275,28276} At 20 µM, it has been shown to arrest asynchronous PC-3 prostate cancer cells in G2/M phase.{28276}
Brand:CaymanSKU:-Available on backorder
Cdc25 dual-specific protein tyrosine phosphatases are important for cell cycle progression and often overexpressed in cancers. Through the removal of inhibitory phosphates, they function to catalyze the activation of cyclin-Cdk complexes. DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.{17980,28275,28276} At 20 µM, it has been shown to arrest asynchronous PC-3 prostate cancer cells in G2/M phase.{28276}
Brand:CaymanSKU:-Available on backorder
Cdc25 dual-specific protein tyrosine phosphatases are important for cell cycle progression and often overexpressed in cancers. Through the removal of inhibitory phosphates, they function to catalyze the activation of cyclin-Cdk complexes. DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.{17980,28275,28276} At 20 µM, it has been shown to arrest asynchronous PC-3 prostate cancer cells in G2/M phase.{28276}
Brand:CaymanSKU:-Available on backorder
DAA1106 is an agonist of the 18 kDa translocator protein TSPO, which was previously known as the peripheral benzodiazepine receptor (PBR), that has an IC50 value of 0.28 nM in a radioligand binding assay.{41208} It is selective for TSPO over central benzodiazepine receptors (CBRs) and GABAA receptors in rat whole brain membranes, as well as a panel of 54 ion channels, uptake/transporters, and secondary messenger receptors at concentrations greater than 10 µM. DAA1106 increases mitochondrial prognenolone formation in rat brain homogenates, which indirectly potentiates GABAA receptor signaling. DAA1106 (1-10 mg/kg) increases the time mice spend in the light area of the light/dark exploration and the time rats spend in open arms of the elevated plus maze in a dose-dependent manner, suggesting a decrease in anxiety-like behavior. Various radiolabeled versions of DAA1106 have been synthesized to study the distribution of PBRs in neurological disease models using positron emission tomography (PET).{41209,41210}
Brand:CaymanSKU:23454 - 1 mgAvailable on backorder
DAA1106 is an agonist of the 18 kDa translocator protein TSPO, which was previously known as the peripheral benzodiazepine receptor (PBR), that has an IC50 value of 0.28 nM in a radioligand binding assay.{41208} It is selective for TSPO over central benzodiazepine receptors (CBRs) and GABAA receptors in rat whole brain membranes, as well as a panel of 54 ion channels, uptake/transporters, and secondary messenger receptors at concentrations greater than 10 µM. DAA1106 increases mitochondrial prognenolone formation in rat brain homogenates, which indirectly potentiates GABAA receptor signaling. DAA1106 (1-10 mg/kg) increases the time mice spend in the light area of the light/dark exploration and the time rats spend in open arms of the elevated plus maze in a dose-dependent manner, suggesting a decrease in anxiety-like behavior. Various radiolabeled versions of DAA1106 have been synthesized to study the distribution of PBRs in neurological disease models using positron emission tomography (PET).{41209,41210}
Brand:CaymanSKU:23454 - 10 mgAvailable on backorder
DAA1106 is an agonist of the 18 kDa translocator protein TSPO, which was previously known as the peripheral benzodiazepine receptor (PBR), that has an IC50 value of 0.28 nM in a radioligand binding assay.{41208} It is selective for TSPO over central benzodiazepine receptors (CBRs) and GABAA receptors in rat whole brain membranes, as well as a panel of 54 ion channels, uptake/transporters, and secondary messenger receptors at concentrations greater than 10 µM. DAA1106 increases mitochondrial prognenolone formation in rat brain homogenates, which indirectly potentiates GABAA receptor signaling. DAA1106 (1-10 mg/kg) increases the time mice spend in the light area of the light/dark exploration and the time rats spend in open arms of the elevated plus maze in a dose-dependent manner, suggesting a decrease in anxiety-like behavior. Various radiolabeled versions of DAA1106 have been synthesized to study the distribution of PBRs in neurological disease models using positron emission tomography (PET).{41209,41210}
Brand:CaymanSKU:23454 - 5 mgAvailable on backorder
DAA1106 is an agonist of the 18 kDa translocator protein TSPO, which was previously known as the peripheral benzodiazepine receptor (PBR), that has an IC50 value of 0.28 nM in a radioligand binding assay.{41208} It is selective for TSPO over central benzodiazepine receptors (CBRs) and GABAA receptors in rat whole brain membranes, as well as a panel of 54 ion channels, uptake/transporters, and secondary messenger receptors at concentrations greater than 10 µM. DAA1106 increases mitochondrial prognenolone formation in rat brain homogenates, which indirectly potentiates GABAA receptor signaling. DAA1106 (1-10 mg/kg) increases the time mice spend in the light area of the light/dark exploration and the time rats spend in open arms of the elevated plus maze in a dose-dependent manner, suggesting a decrease in anxiety-like behavior. Various radiolabeled versions of DAA1106 have been synthesized to study the distribution of PBRs in neurological disease models using positron emission tomography (PET).{41209,41210}
Brand:CaymanSKU:23454 - 500 µgAvailable on backorder
Dabcyl-YVADAPV-EDANS is a fluorogenic substrate for caspase-1.{42039} Upon enzymatic cleavage by caspase-1, EDANS is separated from the Dabcyl quencher and can be used to quantify caspase-1 activity. EDANS displays excitation/emission maxima of 340/485 nm, respectively.
Brand:CaymanSKU:24993 - 1 mgAvailable on backorder
Dabigatran is a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} It also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} Dabigatran has poor bioavailability after oral administration. However, dabigatran etexilate (Item No. 17131) is a double prodrug that has excellent oral bioavailability and undergoes in vivo hydrolytic cleavage to produce dabigatran.{28063,28064}
Brand:CaymanSKU:-Out of stock
Dabigatran is a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} It also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} Dabigatran has poor bioavailability after oral administration. However, dabigatran etexilate (Item No. 17131) is a double prodrug that has excellent oral bioavailability and undergoes in vivo hydrolytic cleavage to produce dabigatran.{28063,28064}
Brand:CaymanSKU:-Out of stock
Dabigatran is a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} It also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} Dabigatran has poor bioavailability after oral administration. However, dabigatran etexilate (Item No. 17131) is a double prodrug that has excellent oral bioavailability and undergoes in vivo hydrolytic cleavage to produce dabigatran.{28063,28064}
Brand:CaymanSKU:-Out of stock
Dabigatran is a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} It also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} Dabigatran has poor bioavailability after oral administration. However, dabigatran etexilate (Item No. 17131) is a double prodrug that has excellent oral bioavailability and undergoes in vivo hydrolytic cleavage to produce dabigatran.{28063,28064}
Brand:CaymanSKU:-Out of stock
Dabigatran acyl-β-D-glucuronide is a major active metabolite of the thrombin inhibitor dabigatran (Item No. 17133). The prodrug of dabigatran, dabigatran etexilate (Item No. 17131), is hydrolyzed by plasma esterases to form dabigatran, which is metabolized primarily by the UDP-glucuronosyltransferase (UGT) isoform UGT2B15 to form dabigatran acyl-β-D-glucuronide.{28064,43581} Dabigatran acyl-β-D-glucuronide increases activated partial thromboplastin time (aPTT) in isolated human platelet-poor plasma equipotently to dabigatran.{43581}
Brand:CaymanSKU:26655 - 1 mgAvailable on backorder
Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran (Item No. 17133), a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} Dabigatran also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} The prodrug dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.{28064} It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.{28064}
Brand:CaymanSKU:-Out of stock
Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran (Item No. 17133), a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} Dabigatran also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} The prodrug dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.{28064} It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.{28064}
Brand:CaymanSKU:-Out of stock
Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran (Item No. 17133), a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} Dabigatran also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} The prodrug dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.{28064} It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.{28064}
Brand:CaymanSKU:-Out of stock
Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:-Out of stock
Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:-Out of stock
Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:-Out of stock
Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:-Out of stock
Dabrafenib-d9 is intended for use as an internal standard for the quantification of dabrafenib (Item No. 16989) by GC- or LC-MS. Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68 and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:28797 - 1 mgAvailable on backorder
Dacarbazine-d6 is intended for use as an internal standard for the quantification of dacarbazine (Item No. 21877) by GC- or LC-MS. Dacarbazine is a DNA alkylating prodrug that is activated by P450 enzymes in liver microsomes.{21297} Following activation, it is converted, through a series of reactions, into a methyldiazonium cation that alkylates DNA at all phases of the cell cycle and induces apoptosis. In vitro, dacarbazine inhibits the growth of B16/F1, A-875, and SK-MEL-5 melanoma and non-cancerous WI-38 lung fibroblast and L-02 hepatocyte cell lines (IC50s = 260, 287, 380, 526, and 367 μM, respectively).{41584} Dacarbazine toxicity to 518A2 and SK-MEL-28 melanoma cell lines increases in a time-dependent manner with IC50 values of 121 and >400 μM, respectively, following a 1 hour incubation and 2.5 and 50 μM, respectively, following a 96 hour incubation.{41585} In vivo, dacarbazine (70 mg/kg, once every 2 days) decreases tumor volume by 59.1% in a B16/F1 murine melanoma model in mice.{41584} Formulations containing dacarbazine have been used in the treatment of metastatic melanoma and for Hodgkin’s lymphoma in combination with other antineoplastic agents.
Brand:CaymanSKU:30771 - 1 mgAvailable on backorder
Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:23730 - 10 mgAvailable on backorder
Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:23730 - 25 mgAvailable on backorder
Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:23730 - 5 mgAvailable on backorder
Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:23730 - 50 mgAvailable on backorder
Daclatasvir-d6 is intended for use as an internal standard for the quantification of daclatasvir (Item No. 23730) by GC- or LC-MS. Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at a concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:29077 - 1 mgAvailable on backorder
Daclatasvir-d6 is intended for use as an internal standard for the quantification of daclatasvir (Item No. 23730) by GC- or LC-MS. Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at a concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:29077 - 5 mgAvailable on backorder
Daclatasvir-d6 is intended for use as an internal standard for the quantification of daclatasvir (Item No. 23730) by GC- or LC-MS. Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at a concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:29077 - 500 µgAvailable on backorder
DADLE is a peptide agonist of δ-opioid receptors (Ki = 2.06 nM in a radioligand binding assay).{37712} It is selective for δ-opioid over κ-opioid receptors (Ki = 16,000 nM) but also agonizes μ-opioid receptors (Ki = 13.8 nM). DADLE inhibits electrically induced contractions in guinea pig myenteric plexus and mouse and rat vas deferens (IC50s = 8.9, 0.73, and 134 nM, respectively). It induces analgesia in the tail-flick and hot plate tests in mice (ED50s = 0.03 and 0.027 nmol per animal, i.c.v.).{52196} DADLE (2.5 mg/kg) decreases infarct volume in a rat model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO).{52197}
Brand:CaymanSKU:28928 - 1 mgAvailable on backorder
DADLE is a peptide agonist of δ-opioid receptors (Ki = 2.06 nM in a radioligand binding assay).{37712} It is selective for δ-opioid over κ-opioid receptors (Ki = 16,000 nM) but also agonizes μ-opioid receptors (Ki = 13.8 nM). DADLE inhibits electrically induced contractions in guinea pig myenteric plexus and mouse and rat vas deferens (IC50s = 8.9, 0.73, and 134 nM, respectively). It induces analgesia in the tail-flick and hot plate tests in mice (ED50s = 0.03 and 0.027 nmol per animal, i.c.v.).{52196} DADLE (2.5 mg/kg) decreases infarct volume in a rat model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO).{52197}
Brand:CaymanSKU:28928 - 10 mgAvailable on backorder
DADLE is a peptide agonist of δ-opioid receptors (Ki = 2.06 nM in a radioligand binding assay).{37712} It is selective for δ-opioid over κ-opioid receptors (Ki = 16,000 nM) but also agonizes μ-opioid receptors (Ki = 13.8 nM). DADLE inhibits electrically induced contractions in guinea pig myenteric plexus and mouse and rat vas deferens (IC50s = 8.9, 0.73, and 134 nM, respectively). It induces analgesia in the tail-flick and hot plate tests in mice (ED50s = 0.03 and 0.027 nmol per animal, i.c.v.).{52196} DADLE (2.5 mg/kg) decreases infarct volume in a rat model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO).{52197}
Brand:CaymanSKU:28928 - 5 mgAvailable on backorder
DADLE is a peptide agonist of δ-opioid receptors (Ki = 2.06 nM in a radioligand binding assay).{37712} It is selective for δ-opioid over κ-opioid receptors (Ki = 16,000 nM) but also agonizes μ-opioid receptors (Ki = 13.8 nM). DADLE inhibits electrically induced contractions in guinea pig myenteric plexus and mouse and rat vas deferens (IC50s = 8.9, 0.73, and 134 nM, respectively). It induces analgesia in the tail-flick and hot plate tests in mice (ED50s = 0.03 and 0.027 nmol per animal, i.c.v.).{52196} DADLE (2.5 mg/kg) decreases infarct volume in a rat model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO).{52197}
Brand:CaymanSKU:28928 - 50 mgAvailable on backorder
DAF-2 is a sensitive fluorescent indicator commonly used for the detection of nitric oxide (NO).{6360,6632} It reacts with NO in the presence of oxygen to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nM, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM.
Brand:CaymanSKU:85160 - 1 mgAvailable on backorder
DAF-2 is a sensitive fluorescent indicator commonly used for the detection of nitric oxide (NO).{6360,6632} It reacts with NO in the presence of oxygen to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nM, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM.
Brand:CaymanSKU:85160 - 100 µgAvailable on backorder
DAF-2 is a sensitive fluorescent indicator commonly used for the detection of nitric oxide (NO).{6360,6632} It reacts with NO in the presence of oxygen to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nM, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM.
Brand:CaymanSKU:85160 - 250 µgAvailable on backorder
DAF-2 is a sensitive fluorescent indicator commonly used for the detection of nitric oxide (NO).{6360,6632} It reacts with NO in the presence of oxygen to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nM, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM.
Brand:CaymanSKU:85160 - 500 µgAvailable on backorder
DAF-2 diacetate is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide (NO).{6360,6632} It is a cell-permeable derivative of DAF-2. Upon entry into the cell, DAF-2 diacetate is transformed into the less cell-permeable DAF-2 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. In the presence of oxygen, DAF-2 reacts with NO to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nm, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM. DAF-2 diacetate can be utilized in cells which produce small amounts of NO, such as endothelial cells, as well as in cells which generate large amount of NO, such as macrophages.{6360,6632}
Brand:CaymanSKU:85165 - 1 mgAvailable on backorder
DAF-2 diacetate is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide (NO).{6360,6632} It is a cell-permeable derivative of DAF-2. Upon entry into the cell, DAF-2 diacetate is transformed into the less cell-permeable DAF-2 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. In the presence of oxygen, DAF-2 reacts with NO to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nm, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM. DAF-2 diacetate can be utilized in cells which produce small amounts of NO, such as endothelial cells, as well as in cells which generate large amount of NO, such as macrophages.{6360,6632}
Brand:CaymanSKU:85165 - 100 µgAvailable on backorder
DAF-2 diacetate is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide (NO).{6360,6632} It is a cell-permeable derivative of DAF-2. Upon entry into the cell, DAF-2 diacetate is transformed into the less cell-permeable DAF-2 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. In the presence of oxygen, DAF-2 reacts with NO to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nm, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM. DAF-2 diacetate can be utilized in cells which produce small amounts of NO, such as endothelial cells, as well as in cells which generate large amount of NO, such as macrophages.{6360,6632}
Brand:CaymanSKU:85165 - 250 µgAvailable on backorder
DAF-2 diacetate is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide (NO).{6360,6632} It is a cell-permeable derivative of DAF-2. Upon entry into the cell, DAF-2 diacetate is transformed into the less cell-permeable DAF-2 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. In the presence of oxygen, DAF-2 reacts with NO to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nm, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM. DAF-2 diacetate can be utilized in cells which produce small amounts of NO, such as endothelial cells, as well as in cells which generate large amount of NO, such as macrophages.{6360,6632}
Brand:CaymanSKU:85165 - 500 µgAvailable on backorder
DAF-FM diacetate is a cell-permeable, fluorescent probe for the detection and bioimaging of nitric oxide (NO) with excitation/emission maxima of 495/515 nm. It passively diffuses across cellular membranes and, once inside cells, is deacetylated by intracellular esterases to become DAF-FM. The fluorescence quantum yield of DAF-FM is ~0.005, but increases about 160-fold, to ~0.81, after reacting with NO.{30226} DAF-FM is advantageous over the NO probe, DAF-2 (Item No. 85160) for several reasons: 1) the spectra of the NO adduct of DAF-FM are independent of pH above pH 5.5; 2) the NO adduct of DAF-FM is significantly more photostable than that of DAF-2; 3) the NO detection limit of DAF-FM (~3 nM) is more sensitive than that of DAF-2 (~5 nM).{30226,30225}
Brand:CaymanSKU:-Available on backorder
DAF-FM diacetate is a cell-permeable, fluorescent probe for the detection and bioimaging of nitric oxide (NO) with excitation/emission maxima of 495/515 nm. It passively diffuses across cellular membranes and, once inside cells, is deacetylated by intracellular esterases to become DAF-FM. The fluorescence quantum yield of DAF-FM is ~0.005, but increases about 160-fold, to ~0.81, after reacting with NO.{30226} DAF-FM is advantageous over the NO probe, DAF-2 (Item No. 85160) for several reasons: 1) the spectra of the NO adduct of DAF-FM are independent of pH above pH 5.5; 2) the NO adduct of DAF-FM is significantly more photostable than that of DAF-2; 3) the NO detection limit of DAF-FM (~3 nM) is more sensitive than that of DAF-2 (~5 nM).{30226,30225}
Brand:CaymanSKU:-Available on backorder